{"id":53912,"date":"2025-11-07T17:26:06","date_gmt":"2025-11-07T11:56:06","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=53912"},"modified":"2025-11-07T17:26:26","modified_gmt":"2025-11-07T11:56:26","slug":"syngene-international-q2-results-2025","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/","title":{"rendered":"Syngene International Q2 Results 2025 Highlights: Net Profit Falls 36.76% &#038; Revenue Up 2.20% YoY"},"content":{"rendered":"<p><a href=\"https:\/\/univest.in\/user\/log-in\"><strong><em>Click and Sign Up to Get Live Updates on Q2 Results&nbsp;<\/em><\/strong><\/a><\/p><p><strong>Syngene International Q2<\/strong><strong><em> Results FY26<\/em><\/strong>: During Q2 FY26, Piramal Pharma&#8217;s profit decreased 36.76% YoY, while revenue increased by 2.20% YoY. The company posted robust numbers, with Q2 PAT at \u20b9 67.1 Crores and revenue at \u20b9910.6 crores. <a href=\"https:\/\/univest.in\/stocks\/syngene\/syngene-international-ltd-share-price-today\">Syngene International<\/a> announced its Q2 results on 5th November 2025.&nbsp;&nbsp;<\/p><div id=\"ez-toc-container\" class=\"ez-toc-v2_0_65 counter-hierarchy ez-toc-counter ez-toc-grey ez-toc-container-direction\">\n<div class=\"ez-toc-title-container\">\n<p class=\"ez-toc-title \" >Table of Contents<\/p>\n<span class=\"ez-toc-title-toggle\"><a href=\"#\" class=\"ez-toc-pull-right ez-toc-btn ez-toc-btn-xs ez-toc-btn-default ez-toc-toggle\" aria-label=\"Toggle Table of Content\"><span class=\"ez-toc-js-icon-con\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n<nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#Syngene_International_Q2_Results_FY26_Extracts_of_FY25_FY26_Consolidated_Figures\" title=\"Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Consolidated Figures)\">Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Consolidated Figures)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#Syngene_International_Q2_Results_FY26_Extracts_of_FY25_FY26_Standalone_Figures\" title=\"Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Standalone Figures)\">Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Standalone Figures)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#Syngene_International_Q2_Results_FY26_Highlights_Q2_FY26_vs_FY25\" title=\"Syngene International Q2 Results FY26 Highlights (Q2 FY26 vs FY25)\">Syngene International Q2 Results FY26 Highlights (Q2 FY26 vs FY25)<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#Syngene_International_Share_Price_Performance\" title=\"Syngene International Share Price Performance\">Syngene International Share Price Performance<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#What_Analysts_Expect_Post_Q2_Results\" title=\"What Analysts Expect Post Q2 Results?\">What Analysts Expect Post Q2 Results?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/univest.in\/blogs-2\/syngene-international-q2-results-2025\/#Recent_Articles\" title=\"Recent Articles\">Recent Articles<\/a><\/li><\/ul><\/nav><\/div>\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Q2_Results_FY26_Extracts_of_FY25_FY26_Consolidated_Figures\"><\/span><strong>Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Consolidated Figures)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td rowspan=\"2\"><strong>Particulars<\/strong><\/td><td colspan=\"2\"><strong>Quarter Ended<\/strong><\/td><\/tr><tr><td><strong>30-09-2025<\/strong><\/td><td><strong>30-09-2024<\/strong><\/td><\/tr><tr><td><strong>Revenue from Operations<\/strong><\/td><td>\u20b9910.6<\/td><td>\u20b9891<\/td><\/tr><tr><td><strong>Profit Before Tax (PBT)<\/strong><\/td><td>\u20b9214.9<\/td><td>\u20b9261.3<\/td><\/tr><tr><td><strong>Profit After Tax (PAT)<\/strong><\/td><td>\u20b967.1<\/td><td>\u20b9106.1<\/td><\/tr><\/tbody><\/table><\/figure><p>(Figures in crores)<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Q2_Results_FY26_Extracts_of_FY25_FY26_Standalone_Figures\"><\/span><strong>Syngene International Q2 Results FY26: Extracts of FY25 &amp; FY26 (Standalone Figures)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><tbody><tr><td rowspan=\"2\"><strong>Particulars<\/strong><\/td><td colspan=\"2\"><strong>Quarter Ended<\/strong><\/td><\/tr><tr><td><strong>30-09-2025<\/strong><\/td><td><strong>30-09-2024<\/strong><\/td><\/tr><tr><td><strong>Revenue from Operations<\/strong><\/td><td>\u20b9830.1<\/td><td>\u20b9821.3<\/td><\/tr><tr><td><strong>Profit Before Tax (PBT)<\/strong><\/td><td>\u20b9191.7<\/td><td>\u20b9225.00<\/td><\/tr><tr><td><strong>Profit After Tax (PAT)<\/strong><\/td><td>\u20b966.2<\/td><td>\u20b996.60<\/td><\/tr><\/tbody><\/table><\/figure><p>(Figures in crores)<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Q2_Results_FY26_Highlights_Q2_FY26_vs_FY25\"><\/span><strong>Syngene International Q2 Results FY26 Highlights (Q2 FY26 vs FY25)<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><ul class=\"wp-block-list\"><li>Syngene International clocked Q2 FY26 consolidated revenue of \u20b9910.6 crores vs \u20b9891.00 crores.\u00a0<\/li>\n\n<li>On the profit front, Syngene International learned a consolidated PAT of \u20b967.1 crore in Q2 FY26. During FY25, the company\u2019s PAT stood at \u20b9106.1 crore.<\/li>\n\n<li>According to the consolidated figures, Piramal Pharma&#8217;s quarterly PAT decreased by 36.76% YoY, while revenue increased by 2.20%.<\/li>\n\n<li>Syngene International clocked Q2 FY26 standalone revenue of \u20b9830.1 crores vs \u20b9821.3 Crores.\u00a0<\/li>\n\n<li>On the profit front, Syngene International learned a standalone PAT of \u20b966.2 crore in Q2 FY26. During FY25, the company\u2019s PAT stood at \u20b996.6 crore.<\/li>\n\n<li>According to the standalone figures, Piramal Pharma&#8217;s quarterly PAT decreased by -31.47% YoY, while revenue increased by 1.07%.<\/li><\/ul><p><strong><em>Download the <\/em><\/strong><a href=\"http:\/\/apps.apple.com\/in\/app\/univest-stocks-investment\/id6443753518\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em>Univest iOS App<\/em><\/strong><\/a><strong><em> or <\/em><\/strong><a href=\"http:\/\/play.google.com\/store\/apps\/details?id=com.univest.capp&amp;hl=en_IN\" rel=\"nofollow noopener\" target=\"_blank\"><strong><em>Univest Android App<\/em><\/strong><\/a><strong><em> to get daily stock recommendations and insightful research pieces!<\/em><\/strong><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Syngene_International_Share_Price_Performance\"><\/span><strong>Syngene International Share Price Performance<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>On the opening bell on 7th November 2025, Syngene International shares opened at \u20b9613.40 per share. However, the initial gains have since eroded, and Piramal Pharma&#8217;s shares are currently trading at \u20b9615.70 per share, which is lower than the opening price.&nbsp;&nbsp;&nbsp;&nbsp;<\/p><p>Considering the long-term achievements, Piramal Pharma&#8217;s shares have yielded returns of approximately -0.89% over the past six months, and one-year returns stand at -32.60%. Over the maximum timeframe, Syngene International shares delivered a 14.35% return to investors.&nbsp;<\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"What_Analysts_Expect_Post_Q2_Results\"><\/span><strong>What Analysts Expect Post Q2 Results?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p>Following Piramal Pharma&#8217;s robust Q2 results, analysts expect its share price to rise. According to analysts, Piramal Pharma&#8217;s share price is expected to reach \u20b9620.00 per share in the coming year; however, in a downturn, it could fall to \u20b9550.60 per share. However, one must ignore stock market volatility and invest in Piramal Pharma&#8217;s shares after thorough research.&nbsp;<\/p><p><strong><em>Disclaimer:<\/em><\/strong><em> Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.<\/em><\/p><h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Recent_Articles\"><\/span><strong>Recent Articles<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2><p><a href=\"https:\/\/univest.in\/blogs\/nestle-q2-results-2025\">Nestle Q2 Results FY26: Q2 PAT Falls 17.38% to \u20b9743.17 Crore; Revenue Up 10.57% YoY<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/inspira-enterprise-india-ipo-details\">Inspira Enterprise India IPO Details: Everything You Should Know about<\/a>&nbsp;<\/p><p><a href=\"https:\/\/univest.in\/blogs\/swaraj-engines-q2-results-fy26\">Swaraj Engines Q2 Results FY26: Q2 PAT Rises 8.88% to \u20b949 Crore; Revenue Up 8.62% YoY<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/hdb-financial-q2-results-2025\">HDB Financial Q2 Results FY26: Q2 PAT Falls 1.5% to \u20b9581 Crore; Revenue Up 13.42% YoY<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/bel-gears-q2-results-expectations\">BEL Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/paytm-q2-results-expectations\">Paytm Gears Up for Q2 Reveal on 4th November; Check Key Expectations Here<\/a><\/p><p><a href=\"https:\/\/univest.in\/blogs\/blue-dart-q2-results-expectations\">Blue Dart Gears Up for Q2 Reveal on 28th October; Check Key Expectations Here<\/a><\/p><p><\/p>","protected":false},"excerpt":{"rendered":"<p>Click and Sign Up to Get Live Updates on Q2 Results&nbsp; Syngene International Q2 Results FY26: During Q2 FY26, Piramal Pharma&#8217;s profit decreased 36.76% YoY, while revenue increased by 2.20% YoY. The company posted robust numbers, with Q2 PAT at \u20b9 67.1 Crores and revenue at \u20b9910.6 crores. Syngene International announced its Q2 results on<\/p>\n","protected":false},"author":23,"featured_media":53913,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[842],"tags":[3205],"class_list":["post-53912","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","tag-syngene-international-q2-results-2025"],"metadata":{"_edit_lock":["1762516587:23"],"_last_editor_used_jetpack":["block-editor"],"rank_math_internal_links_processed":["1"],"rank_math_primary_category":["842"],"rank_math_seo_score":["77"],"rank_math_title":["Syngene International Q2 Results 2025: Net Profit Falls by 36.76% YoY"],"rank_math_description":["Discover the recent updates on the Syngene International Q2 results for FY26. Q2 profit falls by 36.76% YoY to \u20b967.1 crore, and revenue increased by 2.20% YoY. Learn more about the company's financials.\r\n"],"rank_math_focus_keyword":["Syngene International Q2 Results"],"rank_math_robots":["a:2:{i:0;s:7:\"noindex\";i:1;s:8:\"nofollow\";}"],"_thumbnail_id":["53913"],"_edit_last":["23"],"_ez-toc-disabled":[""],"_ez-toc-insert":[""],"_ez-toc-header-label":[""],"_ez-toc-alignment":["none"],"_ez-toc-heading-levels":["a:0:{}"],"_ez-toc-alttext":[""],"_ez-toc-visibility_hide_by_default":[""],"_ez-toc-hide_counter":[""],"_ez-toc-exclude":[""],"_ez-toc-position-specific":["before"],"stm_select_gm_zoom":[""],"stm_agenda":[""],"stm_host":[""],"stm_select_approved_denied":[""],"stm_multiselect_approved":[""],"stm_multiselect_denied":[""],"stm_date":[""],"stm_time":[""],"stm_timezone":[""],"stm_duration":[""],"stm_password":[""],"stm_waiting_room":[""],"stm_join_before_host":[""],"stm_host_join_start":[""],"stm_start_after_participants":[""],"stm_mute_participants":[""],"stm_enforce_login":[""],"stm_alternative_hosts":[""],"top_bar_custom_style":[""],"top_bar_bg":[""],"wc_top_bar_cart_custom_style":[""],"wc_top_bar_cart_color":[""],"wc_top_bar_cart_icon_color_hover":[""],"wc_top_bar_cart_counter_color":[""],"wc_top_bar_cart_counter_color_hover":[""],"wc_top_bar_cart_counter_bg":[""],"wc_top_bar_cart_counter_bg_hover":[""],"top_bar_wpml_switcher_custom_style":[""],"wpml_switcher_color":[""],"top_bar_wpml_switcher_bg":[""],"top_bar_wpml_switcher_bg_hover":[""],"top_bar_wpml_switcher_color_hover":[""],"top_bar_socials_custom_style":[""],"top_bar_socials_color":[""],"top_bar_socials_color_hover":[""],"top_bar_search_custom_style":[""],"top_bar_search_color":[""],"top_bar_search_icon_color_hover":[""],"top_bar_contact_info_style":[""],"top_bar_contact_info_color":[""],"top_bar_contact_info_link_color":[""],"top_bar_contact_info_link_color_hover":[""],"top_bar_contact_info_select_bg":[""],"top_bar_contact_info_select_color":[""],"top_bar_contact_info_select_drop_bg":[""],"top_bar_contact_info_select_items_bg":[""],"top_bar_contact_info_select_items_color":[""],"top_bar_contact_info_select_items_hover":[""],"header_inverse":["default"],"enable_header_transparent":["off"],"header_nav_custom_style":[""],"header_bg":[""],"header_shadow":[""],"wc_cart_custom_style":[""],"wc_cart_icon_color":[""],"wc_cart_icon_color_hover":[""],"wc_cart_counter_color":[""],"wc_cart_counter_color_hover":[""],"wc_cart_counter_bg":[""],"wc_cart_counter_bg_hover":[""],"header_wpml_switcher_custom_style":[""],"header_wpml_switcher_color":[""],"header_wpml_switcher_color_hover":[""],"header_wpml_switcher_bg":[""],"header_wpml_switcher_bg_hover":[""],"header_socials_custom_style":[""],"header_socials_color":[""],"header_socials_color_hover":[""],"header_search_custom_style":[""],"header_search_icon_color":[""],"header_search_icon_color_hover":[""],"header_contact_info_style":[""],"header_contact_info_color":[""],"header_contact_info_link_color":[""],"header_contact_info_link_color_hover":[""],"header_button_custom_style":[""],"header_button_color":[""],"header_button_color_hover":[""],"header_button_bg":[""],"header_button_bg_hover":[""],"header_nav_menu_customize":[""],"header_nav_menu_link_color":[""],"header_nav_menu_link_color_hover":[""],"header_nav_menu_link_color_active":[""],"header_nav_menu_link_arrow_color":[""],"header_nav_menu_link_arrow_color_hover":[""],"header_nav_menu_level_1_bg":[""],"header_nav_menu_level_1_link_color":[""],"header_nav_menu_level_1_link_color_hover":[""],"header_nav_menu_level_1_link_bg_hover":[""],"header_nav_menu_level_1_link_arrow_color":[""],"header_nav_menu_level_1_link_arrow_color_hover":[""],"header_nav_menu_level_2_bg":[""],"header_nav_menu_level_2_link_color":[""],"header_nav_menu_level_2_link_color_hover":[""],"header_nav_menu_level_2_link_bg_hover":[""],"header_mega_menu_bg":[""],"header_mega_menu_title_color":[""],"header_mega_menu_title_color_hover":[""],"header_mega_menu_description_color":[""],"header_mega_menu_description_link_color":[""],"header_mega_menu_description_link_color_hover":[""],"header_mega_menu_color":[""],"header_mega_menu_color_hover":[""],"header_mega_menu_border_color":[""],"header_mega_menu_icons_color":[""],"header_nav_menu_customize_end":[""],"hfe_enabled_notice":[""],"disable_title_box":["default"],"hfe_disabled":[""],"enable_transparent":["default"],"title_box_title_bg_color":[""],"title_box_bg_custom_image":["default"],"title_box_bg_image":[""],"title_box_bg_position":["default"],"metabox_title_box_bg_position_x":[""],"metabox_title_box_bg_position_y":[""],"metabox_title_box_bg_attachment":["default"],"title_box_bg_size":["default"],"metabox_title_box_bg_size_slider":[""],"title_box_bg_repeat":["default"],"disable_title":["default"],"title_box_title_color":[""],"title_box_title_line_color":[""],"disable_breadcrumbs":["default"],"metabox_title_box_breadcrumbs_color":[""],"metabox_title_box_links_color":[""],"metabox_title_box_links_color_hover":[""],"content_bg_transparent":[""],"show_popup_single":[""],"popups_single":[""],"popups_single_event":[""],"popup_single_event_open_delay":[""],"popup_single_event_showing_in":[""],"popup_single_event_date_from":[""],"popup_single_event_date_to":[""],"popup_single_event_time_from":[""],"popup_single_event_time_to":[""],"popup_single_animation":[""],"popup_single_responsive":[""],"separator_footer_copyright_border_t":[""],"name":[""],"email":[""],"phone":[""],"company":[""],"memberId":[""],"testimonial_position":[""],"testimonial_company":[""],"testimonial_bg_img":[""],"testimonial_video_url":[""],"popups_width":[""],"popups_height":[""],"popups_image_bg":[""],"popups_color_bg":[""],"popups_border_radius":[""],"popups_template":[""],"rank_math_analytic_object_id":["4451"],"_wp_page_template":["default"],"rs_page_bg_color":[""],"rank_math_canonical_url":["https:\/\/univest.in\/blogs\/syngene-international-q2-results-2025"]},"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/univest-blog.storage.googleapis.com\/blogs\/wp-content\/uploads\/2025\/11\/07172046\/Syngene-International-Q2-Results-2025-Net-Profit-Falls-by-36.76-YoY.jpg","_links":{"self":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/53912","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/users\/23"}],"replies":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/comments?post=53912"}],"version-history":[{"count":1,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/53912\/revisions"}],"predecessor-version":[{"id":53914,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/posts\/53912\/revisions\/53914"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media\/53913"}],"wp:attachment":[{"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/media?parent=53912"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/categories?post=53912"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/univest.in\/blogs-2\/wp-json\/wp\/v2\/tags?post=53912"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}